$275M Oversubscribed Placement Extends Cash Runway to 2030, Funds Pivotal Osteoporosis Trial
ENTX has more than doubled off its 52-week low of $0.91 on light trading volume (0.2× avg).
Summary
Entera Bio priced a massively oversubscribed $275M private placement at $2.04 per share, a modest discount to the $2.98 market price, signaling strong institutional demand. The deal is led by existing investor BVF Partners and includes top-tier biotech funds like RA Capital and Perceptive Advisors. Proceeds extend the cash runway into 2030, fully funding the Phase 3 registrational program for EB613, an oral osteoporosis drug with positive FDA feedback on its pivotal trial protocol. This follows a May 2026 $10M placement and a June proxy seeking authorization for a significant share increase, indicating the company has now secured the capital needed to execute its late-stage pipeline. The financing removes near-term dilution overhang and positions Entera to reach a potential NDA submission without further equity raises. BVF also gains two board seats, aligning long-term investor interests with the company's clinical milestones.
At the time of this announcement, ENTX was trading at $2.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101M. The 52-week trading range was $0.91 to $3.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.